Durvalumab
- PDF / 169,559 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 80 Downloads / 114 Views
1 S
Multiple sclerosis: case report A 46-year-old man developed multiple sclerosis (MS) during treatment with durvalumab for lung adenocarcinoma [time to reaction onset and outcome not stated]. The man, who had lung adenocarcinoma, was treated with IV durvalumab 120mg following chemoradiotherapy. After 10 infusions, the whole body CT scan revealed a right peritrigonal contrast-enhancing lesion. Subsequent brain MRI showed other sovratentorial white matter lesions. Therefore, the man’s treatment with durvalumab was discontinued. He was treated with a standard course of methylprednisolone with reduction of contrast-enhancing lesions. Thereafter, he was admitted to the neurology department to investigate the cause of demyelinating diseases. It was found that, he experienced fluctuating episodes of paraesthesia of right limbs since 2013. At the neurology department, he underwent clinical and laboratory test which showed a normal result. However, the CSF analysis revealed twenty-three oligoclonal bands. Based on clinical investigation, he was diagnosed with MS secondary to durvalumab. As a corrective measure, he started receiving glatiramer-acetate. Caputo F, et al. Durvalumab and Multiple Sclerosis: A causal link or simple unmasking. European Journal of Neurology 27 (Suppl. 1): 202, Jul 2020. Available from: URL: 803498448 http://doi.org/10.1007/s00228-020-02959-0 [abstract]
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
